Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S C Goldstein

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
The American Journal of the Medical Sciences|November 20, 1997
Nephrotoxicity of high-dose ifosfamide/carboplatin/etoposide in adults undergoing autologous stem cell transplantationD P Agaliotis, O F Ballester, T Mattox, et al.
Bone Marrow Transplantation|May 9, 2017
B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortalityR M Saliba, S Sarantopoulos, C L Kitko, et al.
Bone Marrow Transplantation|October 25, 2011
Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomasV R Paralkar, S D Nasta, K Morrissey, et al.
Seminars in Oncology|May 13, 1998
Defining the role of novel high-dose chemotherapy regimens for the treatment of high-risk breast cancerK K Fields, G J Elfenbein, J B Perkins, et al.
British Journal of Haematology|March 1, 1997
Dexamethasone, cyclophosphamide, idarubicin and etoposide (DC-IE): a novel, intensive induction chemotherapy regimen for patients with high-risk multiple myelomaO F Ballester, L C Moscinski, K K Fields, et al.
Bone Marrow Transplantation|May 26, 2010
Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory acute GVHDA Rager, N Frey, S C Goldstein, et al.
Bone Marrow Transplantation|January 31, 1998
High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiencyO F Ballester, R Tummala, W E Janssen, et al.
Bone Marrow Transplantation|March 15, 2005
Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantationA W Loren, S M Luger, E A Stadtmauer, et al.
Bone Marrow Transplantation|February 7, 2012
High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCTR Tizon, N Frey, D F Heitjan, et al.
Bone Marrow Transplantation|October 6, 2005
Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphomaC Andreadis, S J Schuster, E A Chong, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
The American Journal of the Medical Sciences|November 20, 1997
Nephrotoxicity of high-dose ifosfamide/carboplatin/etoposide in adults undergoing autologous stem cell transplantationD P Agaliotis, O F Ballester, T Mattox, et al.
Bone Marrow Transplantation|May 9, 2017
B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortalityR M Saliba, S Sarantopoulos, C L Kitko, et al.
Bone Marrow Transplantation|October 25, 2011
Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomasV R Paralkar, S D Nasta, K Morrissey, et al.
Seminars in Oncology|May 13, 1998
Defining the role of novel high-dose chemotherapy regimens for the treatment of high-risk breast cancerK K Fields, G J Elfenbein, J B Perkins, et al.
British Journal of Haematology|March 1, 1997
Dexamethasone, cyclophosphamide, idarubicin and etoposide (DC-IE): a novel, intensive induction chemotherapy regimen for patients with high-risk multiple myelomaO F Ballester, L C Moscinski, K K Fields, et al.
Bone Marrow Transplantation|May 26, 2010
Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory acute GVHDA Rager, N Frey, S C Goldstein, et al.
Bone Marrow Transplantation|January 31, 1998
High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiencyO F Ballester, R Tummala, W E Janssen, et al.
Bone Marrow Transplantation|March 15, 2005
Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantationA W Loren, S M Luger, E A Stadtmauer, et al.
Bone Marrow Transplantation|February 7, 2012
High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCTR Tizon, N Frey, D F Heitjan, et al.
Bone Marrow Transplantation|October 6, 2005
Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphomaC Andreadis, S J Schuster, E A Chong, et al.
Pageof 2